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Objectives. The objectives of this study were 1) to evaluate the
effect of different right atrial electrode locations on the efficacy of
low energy transvenous defibrillation with an implantable lead
system; and 2) to qualitate and quantify the discomfort from atrial
defibrillation shocks delivered by a clinically relevant method.
Background. Biatrial shocks result in the lowest thresholds for
transvenous atrial defibrillation, but the optimal right atrial and
coronary sinus electrode locations for defibrillation efficacy in
humans have not been defined.
Methods. Twenty-eight patients (17 men, 11 women) with
chronic atrial fibrillation (AF) (lasting >21 month) were studied.
Transvenous atrial defibrillation was performed by delivering R
wave-synchronized biphasic shocks with incremental shock levels
(from 180 to 400 V in steps of 40 V). Different electrode location
combinations were used and tested randomly: the anterolateral,
inferomedial right atrium or high right atrial appendage to the
distal coronary sinus. Defibrillation thresholds were defined in
duplicate by using the step-up protocol. Pain perception of shock
delivery was assessed by using a purpose-designed questionnaire;
sedation was given when the shock level was unacceptable (toler-
ability threshold).
Results. Sinus rhythm was restored in 26 of 28 patients by using
at least one of the right atrial electrode locations tested. The
conversion rate with the anterolateral right atrial location (21
[81%] of 26) was higher than that with the inferomedial right
atrial location (8 [50%] of 16, p < 0.05) but similar to that with
the high right atrial appendage location (16 [89%] of 18, p >
0.05). The mean defibrillation thresholds for the high right atrial
appendage, anterolateral right atrium and inferomedial right
atrium were all significantly different with respect to energy (3.9 6
1.8 J vs. 4.6 6 1.8 J vs. 6.0 6 1.7 J, respectively, p < 0.05) and
voltage (317 6 77 V vs. 348 6 70 V vs. 396 6 66 V, respectively,
p < 0.05). Patients tolerated a mean of 3.4 6 2 shocks with a
tolerability threshold of 255 6 60 V, 2.5 6 1.3 J.
Conclusions. Low energy transvenous defibrillation with an
implantable defibrillation lead system is an effective treatment for
AF. Most patients can tolerate two to three shocks, and, when the
starting shock level (180 V) is close to the defibrillation threshold,
they can tolerate on average a shock level of 260 V without
sedation. Electrodes should be positioned in the distal coronary
sinus and in the high right atrial appendage to achieve the lowest
defibrillation threshold, although other locations may be suitable
for certain patients.
(J Am Coll Cardiol 1997;30:1324–30)
©1997 by the American College of Cardiology
The efficacy and safety of converting atrial fibrillation (AF) by
delivering low energy shocks between intracardiac catheters
with shock vectors encompassing both the left and right atria
have been demonstrated in animal and human studies (1–10).
These studies suggest that the use of intracardiac catheter-
based electrodes in combination with an implantable device
would be feasible, but patient and physician acceptance of such
a device is yet to be determined. Previous studies (11–13) have
shown the relation between the defibrillation threshold with
different defibrillation waveforms, size of defibrillation elec-
trodes and electrode configurations. A lower defibrillation
threshold may have a significant impact on device size and
longevity and, possibly, on patient tolerance. To date, the most
efficient and most commonly used method of atrial defibrilla-
tion in humans has been delivery of biphasic shocks between
electrodes positioned in the coronary sinus and the lateral right
atrium.
Unlike patients with ventricular fibrillation and an implant-
able ventricular defibrillator, who may become hemodynami-
cally unstable during the arrhythmia, patients with paroxysmal
AF are likely to be conscious during their arrhythmia. Thus,
the ability of patients to tolerate defibrillation shocks without
sedation remains one of the main unanswered questions
concerning use of an implantable atrial defibrillator. In a study
using a 20-V step-up incremental shock protocol for trans-
venous defibrillation beginning at a shock level of 20 V, the
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mean tolerated energy level of a shock delivered without
sedation was ;120 V, a level far below the mean successful
voltage (237 V) for restoration of sinus rhythm (7). This
finding raised concern that sedation will be routinely required
for successful defibrillation. However, the reported method of
threshold determination, although potentially more accurate
than using a higher starting energy level, may not be applicable
to device-mediated patient treatment. Clinically, an initial
shock level that is moderately high—that is, closer to the level
likely to result in successful arrhythmia conversion—should
decrease the number of shocks delivered and thus might make
this form of therapy more acceptable.
We hypothesized that defibrillation thresholds would differ
significantly with different atrial electrode locations when an
implantable lead system was used clinically. Our secondary
hypothesis was that patients would tolerate shocks of a higher
intensity than values previously reported if the starting shock
intensity was closer in intensity to the predicted defibrillation
threshold.
Methods
Patient selection (Table 1). All patients gave written in-
formed consent before the procedure, and the protocol was
approved by the ethics committee of the University of Hong
Kong. Transvenous atrial defibrillation was performed in 28
patients (17 men, 11 women) with electrocardiographically
documented AF for $1 month (range 1 to 192 months, exact
duration unknown in 2 patients). Patients with the following
conditions were excluded from study: 1) reversible causes of
AF, 2) significant valvular heart disease, 3) unstable angina or
recent onset myocardial infarction, 4) class III or IV heart
failure, and 5) evidence of left atrial clot or thrombi. The
patients had a mean age of 62 6 9 years and a mean left atrial
diameter of 4.5 6 0.6 cm. A detailed clinical examination, chest
radiography and transthoracic and transesophageal echocardi-
ography were routinely performed. Other clinical characteris-
tics of the patients and the electrode locations tested are
summarized in Table 1. All antiarrhythmic agents were
stopped at least 5 half-lives before the procedure.
Anticoagulation. All patients were treated with oral anti-
coagulation using warfarin to achieve an international normal-
ized ratio (INR) of 2 to 3 for $3 weeks before the procedure.
Oral anticoagulation was discontinued 2 days before the
procedure and was replaced with an intravenous heparin
infusion. The heparin infusion was stopped 4 h before and
restarted 4 h after the procedure. The INR was checked daily
and immediately before the procedure; the minimal INR value
deemed safe for venous puncture was ,1.5. Oral anticoagula-
tion was restarted after the cardioversion and was continued
for $3 months. Heparin infusion was discontinued when the
therapeutic INR of 2 to 3 was again achieved.
Defibrillation lead placement. Defibrillation testing was
performed with the patient in a fasting state without sedative
or hypnotic premedication. Local anesthesia with bupivacaine
(0.25%) was given before venous puncture. Two 8F sheaths
were introduced into the left subclavian vein from separate
punctures. Implantable defibrillator leads were positioned in
the distal coronary sinus and right atrium; exact locations for
testing were determined on the basis of a randomized location
order.
The electrode placed in the coronary sinus was on a
transvenous passive fixation lead (model 7107, Perimeter CS
lead, InControl, Inc.), with a nominal defibrillator coil length
of 6 cm and an electrode surface area of 4.7 cm2. The
defibrillation coil has a pigtail-like spring coil of 2.5 turns that
was deployed when the stylet was withdrawn (Fig. 1). With use
of a stiff stylet shaped with a gentle curve, the lead was
Abbreviations and Acronyms
AF 5 atrial fibrillation
ANOVA 5 analysis of variance
INR 5 international normalized ratio
Table 1. Clinical Characteristics of Patients Undergoing
Transvenous Atrial Defibrillation and the Voltage Thresholds From
the Electrode Locations Tested
Pt
No.
Age (yr)/
Gender
Duration of
AF (mo)
LA Size
(cm)
RA Location Threshold (V)
HRA LRA MRA
1 63/F 3 4.1 380/340 ND
2 59/F 24 4.9 260/260 ND
3 65/M 96 3.3 300/300 400/400
4 80/M 1 4.6 400/400 ND
5 58/M 2 4.4 380/340 380/380
6 76/F 1 5.1 ND ND
7 70/M 2 4.6 300/340 ND
8 78/M 24 4.9 ND 380/380
9 65/M 108 5.1 400/400 400/400
10 65/F 19 4.6 220/180 300/380
11 77/F 1.5 3.8 300/300 220/220
12 57/M 20 5.3 400/380 ND
13 65/M 1.5 5.2 ND 400/400
14 59/F 5 4.7 260/220 260/260
15 65/F 68 4.2 380/400 ND
16 54/M 36 3.2 380/300 340/400
17 66/M 24 3.8 340/340 260/340
18 43/F 24 5.2 340/300 ND
19 59/M 12 4.4 220/220 400/340
20 60/M 96 4.2 ND ND ND
21 57/F 9 5.1 ND ND 340/400
22 50/M 4 5.6 340/340 400/400 ND
23 52/M 39 4.3 300/260 300/300 ND
24 69/F 36 4.7 340/260 340/300 260/220
25 55/M 192 5.4 380/380 340/260 ND
26 48/M . 1 3.5 260/180 380/300 400/400
27 66/F 2 Unk 300/380 300/220 ND
28 65/M . 1 4.5 220/220 260/260 220/260
AF 5 atrial fibrillation; F 5 female; HRA 5 high right atrial appendage;
LA 5 left atrial; LRA 5 anterolateral right atrium; M 5 male; MRA 5
inferomedial right atrium; ND 5 defibrillation not achieved with 400 V; Pt 5
patient; Unk 5 unknown.
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advanced as distally as possible into the coronary sinus, making
certain that it had not advanced too anterior to beyond the
margin of the left atrium and was therefore considered ad-
vanced too far and into the descending vein onto the ventricle.
The philosophy behind the positioning of this lead was to
mimic the clinical implantation of such a lead and to use this
same coronary sinus lead location to evaluate each of the right
atrial lead locations.
The second defibrillation lead (model 7203, Perimeter RA
lead, InControl Inc.) for the right atrium was an active fixation
screw-in lead, with a nominal defibrillation coil length of 6 cm
and an electrode surface area of 5.2 cm2. The right atrial
defibrillation lead was advanced under fluoroscopic control
while maintaining counterclockwise rotation of the lead body.
Once the lead tip reached the right atrium, the straight stylet
was withdrawn. With the use of a manually shaped stylet
(either J-shaped for the appendage location or with a gentler
curve for the other locations), the tip of the lead was posi-
tioned in one of the three right atrial electrode locations for
defibrillation threshold testing.
The three electrode locations were determined by dividing
the atrial chamber into three approximately equal but discrete
parts based on the fluoroscopic silhouette of the right atrium.
These three electrode locations were defined as the high right
atrial appendage, anterolateral right atrium and inferomedial
right atrium (Fig. 2). The lead was advanced so that the coil
electrode was located within the atrium (upper third for the high
right atrial appendage location, lateral third for the anterolat-
eral right atrial location or the inferior third of the right
atrium, and in contact with the inferior right atrial wall, for the
inferomedial right atrial location). After the desired right atrial
location was reached, the lead tip was affixed to the right atrial
wall by turning the lead body clockwise over the stylet with
three to five complete turns. The stylet was subsequently
removed and the coil electrode adjusted with lead advance-
ment and withdrawal so that the coil electrode was located
within the desired third of the right atrium. As with the
coronary sinus lead, this study was designed to mimic the
clinical use of the lead system; therefore, electrode location
was made as consistent as possible within the clinical confines
of the anatomy of a given patient to allow clinical comparison
of three electrode locations.
Two 6F pacing catheters were also positioned. One was
placed in the right atrium (for AF induction) and one in the
right ventricle (for shock synchronization); both were ad-
vanced from the right femoral vein.
External atrial defibrillator. The defibrillation leads were
connected to a custom-built external defibrillator (XAD, In-
Control, Inc.), whereas the temporary catheters were attached
to a programmable stimulator (model 5328, Medtronic Inc.)
and to the recording equipment. Surface electrocardiogram,
atrial and ventricular electrograms and arterial blood pressure
were continuously monitored by using a chart recorder (Min-
gograf 7, Siemens Ltd, Sweden) at a paper speed of 50 mm/s.
A test shock of 20 V was first delivered to assess R wave
synchronization and the integrity of the defibrillation system.
R wave-synchronized, 3/3 ms duration biphasic shocks were
then delivered, starting with a shock intensity of 180 V. The
shock intensity was increased in steps of 40 V until sinus
rhythm was restored (atrial defibrillation threshold) or until
a shock of the maximal intensity deliverable from the device
(400 V) was reached. The shock with the lowest intensity that
resulted in successful conversion was considered the defibril-
lation threshold. To allow for statistical analysis of thresholds,
one step (40 V) higher than the maximal intensity applied was
used to represent the defibrillation threshold when shocks
failed to convert AF with use of a particular right atrial lead
location. If sinus rhythm was restored and sustained for
$1 min, AF was reinduced by rapid atrial pacing. The defi-
brillation threshold was then redetermined by using the same
right atrial lead location under test, again using the 40-V
step-up protocol; however, this second threshold determina-
tion used a starting intensity that was two steps (80 V) lower
than the previously determined threshold. Should any of the
initial shocks (either 180 or 80 V less than the first threshold)
successfully convert the AF, the shock intensity was decreased
by two steps (80 V) and the 40-V step-up protocol was started
from this initial failed shock level. After determination of two
Figure 1. Implantable lead system used for transvenous atrial defibril-
lation. Upper panel, Coronary sinus lead (top) and right atrial active
fixation lead (bottom). Lower panel, Spring coil of the coronary sinus
lead after the stylet is withdrawn.
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thresholds for successful defibrillation or after the delivery of
two 400-V shocks that failed to convert AF, the right atrial
defibrillation lead was repositioned to the next location and the
defibrillation thresholds were determined by using the same
method.
Lead sequence testing. The right atrial electrode was ran-
domly positioned in both the anterolateral and inferomedial
right atrial locations in 9 patients, in both the anterolateral
right atrial and high right atrial appendage locations in 10
patients and in all three locations in 9 patients. In some
patients, because of the length of the procedure, only two lead
locations were tested.
Pain perception assessment. The method of assessing dis-
comfort level and the patient discomfort questionnaire were
explained to all patients in detail before the defibrillation
procedure. Shock perception was assessed by using a 10-point
visual analog scale. On this scale, 0 represented “not felt,”
whereas 10 represented “extremely uncomfortable.” The shock
intensity that resulted in a perception score of 10 was consid-
ered the tolerability threshold. All patients were warned before
each shock application, but the shock intensity was not dis-
closed. Once the tolerability threshold was reached, patients
were asked to complete a discomfort questionnaire (Table 2).
Patients were then sedated with midazolam (0.05 mg/kg body
weight) and pethidine (0.5 mg/kg); additional doses were given
as required.
Statistical analysis. Repeated measures analysis of vari-
ance (ANOVA) was used to compare the defibrillation thresh-
old for the different right atrial electrode locations and to
compare the first and second thresholds determined for each
of these locations. Rates of successful conversion for the
different right atrial electrode locations were compared by
using the Fisher exact test. All results are expressed as mean
value 6 1 SD; a p value , 0.05 was considered statistically
significant.
Results
Defibrillation efficacy and threshold. Evaluation of overall
efficacy of the procedure revealed that sinus rhythm was
restored in 26 of the 28 patients. The procedure did not induce
ventricular arrhythmia or result in other complications. The
Figure 2. Cine images showing different electrode locations during
transvenous atrial defibrillation. Upper panel, High right atrial ap-
pendage location (HRA). Middle panel, Anterolateral right atrial
location (LRA). Lower panel, Inferomedial right atrial location
(MRA). Quadripolar pacing catheters (not labeled) were placed in the
right atrium and right ventricle (RV). CS 5 distal coronary sinus.
Table 2. Results of Questionnaire Used to Assess Patient
Discomfort at Highest Tolerable Shock Level (n 5 19 patients)
1. Was your pain/discomfort diffuse or localizable?
Diffuse (0%); localized (100%)
Location: anterior chest (87%); epigastric (13%)
2. Did the pain/discomfort radiate?
Yes (5%); no (95%)
Location: neck and both arms
3. Was the pain/discomfort sharp or dull?
Sharp (0%); dull (100%)
4. Were you short of breath?
Yes (18%); no (82%)
5. Did you notice any muscle contraction?
Yes (60%); no (40%)
6. How long did the discomfort last?
5–30 s (95%); 1 min (5%)
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number of patients whose arrhythmia was converted by using
the inferomedial right atrial electrode location (8 [50%] of 16)
was less than the number whose arrhythmia was converted by
using either high right atrial appendage or anterolateral right
atrial electrode locations (16 [89%] of 18 and 21 [81%] of 26,
respectively, p , 0.05). The latter two electrode locations did
not differ significantly in the number of patients with arrhyth-
mia conversion (p . 0.05). The mean defibrillation thresholds
for the high right atrial appendage, anterolateral right atrial
and the inferomedial right atrial electrode locations are shown
in Figure 3; all were significantly different with respect to
energy (3.9 6 1.8 vs. 4.6 6 1.8 vs. 6.0 6 1.7 J, respectively, p ,
0.05) and voltage (317 6 77 vs. 348 6 70 vs. 396 6 66 V,
respectively, p , 0.05). However, individual thresholds for a
given patient did not always follow the trend of the means for
the different right atrial electrode locations (Table 1). There
was no significant difference in when the first and second
defibrillation thresholds were compared for the same right
atrial electrode location (p . 0.05).
Pain perception in transvenous atrial defibrillation. Four
patients tolerated the maximal shock level (400 V) without
sedation, and one patient requested sedation before position-
ing of the leads and shock delivery. Sinus rhythm was restored
in two patients (at 220 and 400 V, respectively) before the
tolerability threshold was reached. Two patients had successful
defibrillation at their respective tolerability thresholds of 220
and 340 V. The need for sedation at different shock levels is
shown in Table 3. After excluding patients in whom AF was not
converted even at 400 V without sedation and patients who
had successful defibrillation before the tolerability threshold
was reached, the tolerability threshold in the remaining 22
patients was 2.5 6 1.3 J, 255 6 60 V (range 1 to 5.6 J, 180 to
380 V). On average, patients tolerated 3.4 6 2 shocks either
before cardioversion was achieved (5 patients) or before the
patient requested sedation (17 patients).
All patients in whom the questionnaire was used (n 5 19)
described the perception at the tolerability threshold as a dull
discomfort mainly localized in the anterior chest (Table 2). In
18 of the 19 patients, discomfort disappeared 5 to 30 s after
shock delivery; in 1 patient the discomfort lasted ;1 min.
Three patients reported mild to moderate shortness of breath.
Discussion
New findings of this study. The two new findings in this
study relate to the clinical use of an implantable atrial defibril-
lator that utilizes a right atrium to coronary sinus shock vector.
This study demonstrated that the site selected for placement of
the right atrial defibrillation electrode has a significant impact
on the atrial defibrillation threshold. Therefore, this study can
provide guidance in the clinical positioning of such a lead and
its electrode. Second, comparison of the shock tolerability data
collected in this study with the results of other studies of
transvenous atrial defibrillation suggests that the number of
shocks may have a greater effect than shock intensity on
patient perception of shock tolerability. This finding has im-
portant implications for the determination of patient accep-
tance of internal defibrillation therapy for AF and the clinical
use of an implantable atrial defibrillator.
Defibrillation threshold and lead locations. The energy
requirement for transvenous atrial defibrillation is only ;2%
to 5% of the energy required for transthoracic defibrillation
(1–8) and ;2% of the energy requirement in an early inves-
tigation (14) using an intracardiac defibrillation catheter and
an external plate on the left posterior chest. Shock delivery
with different electrode locations has been found to affect the
distribution of energy and, therefore, the defibrillation thresh-
old. In animal studies (11,12), it has been demonstrated that
right to left shock vectors encompassing both atria had signif-
icantly lower defibrillation thresholds than right-sided vectors,
and shock delivery between the right atrium and coronary sinus
was more efficacious than shock delivery using other vectors. A
Figure 3. Defibrillation thresholds from shocks with
different right atrial locations. Abbreviations as in
Figure 2.
Table 3. Requirement for Sedation at Different Shock Levels
During Low Energy Transvenous Atrial Defibrillation
Shock Level (V) Without Sedation* With Sedation*
180 27 (100%) 0
220 24 (89%) 3
260 14 (56%) 11
300 10 (40%) 15
340 9 (43%) 12
380 5 (31%) 11
400 4 (27%) 11
*Data presented are number (%) of patients.
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recent study (15) assessed the effect of different lead locations
on defibrillation threshold in a group of patients with hetero-
geneous cardiac diseases. The investigators found that a mean
defibrillation threshold of 9.9 J was required in three random-
ized positions tested (right atrium and skin patch, right atrium
and right ventricle, and right atrium to superior vena cava,
which had the lowest defibrillation threshold). A trend toward
a lower defibrillation threshold in the right atrium to left
pulmonary artery (five patients) or coronary sinus vector (two
patients) was seen in this nonrandomized study, although the
defibrillation thresholds were only 7.5 and 2 J in the two
patients with the right atrium to coronary sinus configuration.
Thus, the available data on lead location in humans suggest
that a right atrium to coronary sinus vector may be associated
with the lowest defibrillation threshold. However, none of
these studies examined the site of the right atrium associated
with the lowest defibrillation threshold, which may have a
significant impact on patient tolerability and battery longevity.
To our knowledge, our study is the first to examine the effects
of different right atrial electrode locations. We demonstrated
that high right atrial appendage electrode location appears to
have, on average, a lower atrial defibrillation threshold than
that of an anterolateral right atrial electrode location. The
inferomedial right atrial electrode location had the lowest
threshold and also the smallest number of patients whose
arrhythmia was converted with use of this electrode location.
This finding is at odds with the results from a study in sheep
(16) in which the superior right atrial location had a higher
defibrillation threshold (1.25 6 0.52 J) than that of a low right
atrial appendage or anterolateral right atrial location (0.92 6
0.48 and 0.77 6 0.31 J, respectively, p , 0.05). This difference
may be due to the difference between sheep and human
anatomy or to the use of temporary catheters in the animal
study and leads of a permanent type in this clinical study.
Although the high right atrial appendage electrode location
in our study resulted in the lowest mean defibrillation thresh-
old, it is important to note that this finding was not consistent
for all patients tested. Second, it is necessary to consider, in
addition to the threshold data, the number of patients whose
arrhythmia could be converted by using each of the three right
atrial electrode locations tested. These two issues taken into
account, we believe that our study data can serve as a guide for
the clinical placement of right atrial defibrillation leads. On the
basis of our results, we recommend that clinicians first attempt
to locate the right atrial electrode in the high right atrial
appendage; if thresholds are inadequate for defibrillation or
tolerability with this electrode location, the anterolateral right
atrium should then be tried. The inferomedial right atrial
electrode location, given the smaller number of patients in this
study with successful arrhythmia conversion and a higher mean
threshold, would be unlikely to provide either an adequate
threshold or an adequate likelihood of successful conversion.
Therefore, we anticipate that this electrode location would be
used only in rare situations. Lastly, the threshold for an
electrode location must be considered against the difficulty in
lead placement, the location clinically obtainable in a given
patient with the coronary sinus electrode, and stresses on the
tip of the right atrial lead. The lateral right atrium is potentially
the easiest location to achieve, requiring less stress on the lead
tip than other sites; however, this location is less distant from
a more proximal coronary sinus electrode location, which
included a lesser amount of atrial myocardium in the elevated
field.
The atrial defibrillation threshold we obtained was only half
the value obtained in a similar clinical study by Saksena et al.
(15), but it is similar to thresholds reported in a study (7) using
temporary catheters in the right atrium to coronary sinus
vector. This finding may be due to the fact that the majority of
patients in our study did not have major underlying cardiac
diseases. However, the mean left atrial diameter in our study,
4.5 cm, was identical to that reported by Saksena et al. (15).
Additionally, chronic AF was present in all patients in our
study but in only 50% of the patients of Saksena et al. (15).
Preliminary data (6,10) suggested that chronic AF is associated
with a higher defibrillation threshold. Thus, we believe that the
lower defibrillation threshold observed in our study may be
attributed to the lead locations we used. The study of patients
without significant structural heart disease is a logical first step
in the investigation of an implantable atrial defibrillator.
Further study will be required to assess the efficacy of this
technique in different patient groups.
Tolerability of low energy transvenous atrial defibrillation.
Previous data on the tolerability of low energy transvenous
atrial defibrillation are limited. Murgatroyd et al. (7) per-
formed low energy transvenous defibrillation in 4 patients with
spontaneous AF and 18 patients with induced AF and reported
a maximal tolerable shock intensity of 180 V (1.0 J). Apart
from 2 of their patients who had sinus rhythm restored with
“severely uncomfortable” shocks (140 V) and 3 who could not
tolerate the smallest shock intensity (10 or 20 V), the other 17
patients required sedation before the threshold voltage (237 6
55 V) was reached. Another study (17), using catheters in the
right atrial appendage and the coronary sinus for converting
AF in 10 patients, also reported a fairly low tolerability. All
patients in that study required sedation at a shock energy
intensity of ,2 J. Tolerability data were also limited in a third
study (15); only 2 of 18 patients could tolerate the effective
shock without sedation. The tolerability in our patients was
significantly higher than that of the patients in these studies. In
our study, the mean tolerability threshold was not too distant
from the defibrillation threshold, and a few patients tolerated
the maximal voltage tested (400 V) without sedation.
Because the study of Murgatroyd et al. (7) used a 20-V
initial shock intensity, more shocks were required before sinus
rhythm was restored. Additionally, in that study, as in our
study, two to three shocks were delivered before the tolerabil-
ity threshold was reached. Therefore, the tolerability of atrial
defibrillation shocks may be related more to the cumulative
effect of shock delivery—that is, the total number of shocks
delivered—than to the intensity of individual shocks. There-
fore, it would appear that patient tolerability is improved if the
first shock level is close to or slightly above the predicted
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defibrillation threshold. A gradual step-up protocol with a low
starting intensity used for therapeutic conversion in patients
undergoing internal atrial defibrillation or with an implantable
atrial defibrillator will probably be poorly tolerated. As most
patients will tolerate a mean of two to three shocks, a
subsequent “rescue” shock should probably be of a sufficiently
higher intensity to ensure successful defibrillation. With the
shock delivery methodol employed in this study, we demon-
strated improved patient tolerability by using this concept—
namely, increasing the shock intensity so that the number of
shocks can be limited.
Psychologic factors, such as patient preparation in the form
of a low intensity warning shock and patient-perceived benefit
from shock delivery, may also play a critical role with respect to
patient tolerability. Methods that lower the defibrillation
threshold, such as concomitant administration of an antiar-
rhythmic agent (6) or the use of rapidly absorbed medications
to relieve shock-induced discomfort, may further enhance
patient acceptability of a low energy implantable atrial defi-
brillator. Additionally, technologic advances in waveform and
electrodes may further increase the tolerability of internal
atrial defibrillation.
Limitations of the study. Our study was concerned with
atrial defibrillation threshold in patients with chronic AF, and
it is likely that a lower defibrillation threshold will be obtained
for acute onset AF, as has been shown by using temporary lead
systems (10). However, the higher energy requirements of
chronic AF enabled us to assess patient tolerability to higher
intensity shocks, thereby adding important data to the clinical
application of this technique. Although the reduced defibrilla-
tion energy requirement—3.9 rather than 6.0 J—may still be
perceived by the patients, it is conceivable that a similar
reduction would contribute to better patient tolerance in
patients with acute onset AF. Further studies will be needed to
evaluate the long-term changes in defibrillation threshold and
tolerability in patients with an implantable atrial defibrillator
system. This study was underpowered to assess the effect of
lead location on discomfort, a factor that might theoretically
have an effect on clinical practice as important as that of
defibrillation threshold.
Because our study utilized the initial, chronic episode of AF
in determining the first defibrillation threshold, it could be
argued that this initial threshold would be higher than the
thresholds obtained for subsequent induced episodes of AF.
However, previous studies by our group (6) in similar patients
have shown that thresholds are not higher for spontaneous,
longer-lasting episodes than for induced AF. Additionally, this
study was designed so that each threshold was redetermined at
each right atrial location site, thereby determining a threshold
for both the long-lasting episode and for induced AF. Statis-
tical analysis with ANOVA of the initial threshold versus
subsequent thresholds, allowing for the difference in right
atrial location, showed that the initial threshold was not
significantly different from the subsequent threshold in our
patient group (p . 0.05). Therefore, concerns surrounding this
issue should not diminish the strength of the conclusions and
findings reported herein.
Conclusions. Low energy transvenous defibrillation with
an implantable defibrillation lead system is an effective treat-
ment for restoring sinus rhythm in patients with AF. Defibril-
lation leads should be implanted so that the electrode is
located in the high right atrial appendage or, secondarily, in
the anterolateral right atrium when used with a second lead in
the distal coronary sinus. When a moderate rather than a low
initial shock level is used, most patients can tolerate the
defibrillation shock level of 260 V and two to three shocks. To
improve patient tolerability, a starting shock level close to the
defibrillation threshold should be used in a shock delivery
protocol.
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